• Search
  • Login
  • Register
Menu
  • Lastest issue
  • Home
  • News
  • CongressUpdate
  • Specials
  • Guidelines
  • Links
All
  • All
  • BJMO articles
  • Blog articles
  • Specials
Forgot Password? Not a member yet? Register here

Category

All
  • Alle
  • Pharma News
  • Health of Tomorrow
  • Opinion
  • Art Corner
  • Fundraising
  • Prevention
  • Science
  • Clinical Practice
  • Corona
  • Cancer trials
  • Healthy Living
  • Medical Research
  • Art on View
  • Viewpoints
  • Therapy
  • Health Innovation
  • Podcasts
  • Editor's pick
  • Special
  • BSMO Meeting 2021
  • Covid-19
  • EADO 2021
  • Society Announcement
Medical Research

[177Lu]Lu-PSMA-617 delays the time to HRQOL worsening and skeletal events in prosta...

subscribe Latest issue All issues Newsletters
Index latest issue
  • INTRODUCTION
  • Emerging therapies in gynaecological cancers (part 2): Endometrial cancer – Adjuvant and metastatic settings
  • Global perspectives and challenges of breast cancer care in Europe
  • Anti-IL6 receptor antibody for the treatment of immune checkpoint-related hemophagocytic lymphohistiocytosis
  • Implementation of Electronic Patient-Reported Outcome Measures after Palliative Radiotherapy: Bridging the Knowledge Gap
  • Highlights of the ENETS (European Neuroendocrine Tumour Society) congress 2025
  • EMUC24 report: Highlights and key takeaways at the multidisciplinary congress
  • Refining Stereotactic Body Radiotherapy for Oligometastatic Gynaecologic Tumours: Key Insights from 2024
Cancer trials

Smartphone App for Postoperative Home Monitoring improves quality of recovery after Oncologic ...

Cancer trials

FTD–TPI plus bevacizumab prolongs the longer overall survival of patients with refractory me...

Clinical Practice

Lorlatinib: a new player in the evolving first-line treatment landscape for patients with ALK-...

Pharma News

Osimertinib plus chemotherapy prolongs PFS in EGFR-mutated NSCLC patients

Cancer trials

Lack of survival benefit with adjuvant chemotherapy in locally advanced cervical cancer

Cancer trials

First-line tislelizumab plus chemotherapy prolongs survival in metastatic or advanced ESCC

Previous 13 14 15 16 17 18 19 Next
Top

Join our newsletter

  • This field is for validation purposes and should be left unchanged.
  • About BJMO
  • Ads & sponsoring
  • Vacancies
  • Disclaimer
  • Privacy
  • Contact

BJMO is published by Ariez International BV, Westzijde 22, 1506 EE Zaandam, The Netherlands

© BJMO 2025

Manage Cookie Consent

To provide the best experiences, we and our partners use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us and our partners to process personal data such as browsing behavior or unique IDs on this site and show (non-) personalized ads. Not consenting or withdrawing consent, may adversely affect certain features and functions.

Click below to consent to the above or make granular choices. Your choices will be applied to this site only. You can change your settings at any time, including withdrawing your consent, by using the toggles on the Cookie Policy, or by clicking on the manage consent button at the bottom of the screen.

Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
Statistics

Marketing

Features
Always active

Always active
Manage options Manage services Manage {vendor_count} vendors Read more about these purposes
View preferences
{title} {title} {title}